The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?

What you need to know to avoid costly delays in your API scale-up

Whitepaper

Traditionally, the development of a small-scale synthesis for an active pharmaceutical ingredient (API) and its scale-up to meet the materials demand for clinical trial phases is a sequential activity that passes through multiple sets of hands. The developer must be prepared to encounter and react to any changes to the API’s quality attributes—such as by-product profile and physical form—even if the synthesis used at a small scale is the same one used at a large scale. If undesirable effects occur during the development process that negatively impact API scale-up, it can prevent a company from delivering a product with reliable quality and efficacy. For these reasons, a company must be aware of any potential conditions that could occur at a small-scale that could create major issues during commercial scale-up.